1. GlaxoSmithKline has stopped phase III clinical trials on a cancer immunotherapeutic drug after analysis showed they may not be able to find a subpopulation of patients that would benefit from the drug.
2. Forty percent of the largest pharmaceutical companies have a board member serving in a leadership position at an academic medical center.
3. Gilead’s Sovaldi, a Hepatitis C treatment drug, is on track to have one of the highest grossing first year sales for a new drug. Sales could potentially reach $9 billion in its first year.
4. Baxter announced plans to create two separate, independent global healthcare companies focusing on biopharmaceuticals and life-saving medical products.
5. Shire Pharmaceuticals has recalled three lots of VPRIV, a long-term intravenous enzyme replacement therapy for patients with type 1 Gaucher disease, due to stainless steel and barium sulfate particulate matter found in a few vials.
6. The manufacturer of OxyContin, Purdue Pharma, has developed a tamper-resistant hydrocodone drug that prevents users from altering the drug for misuse or abuse.
7. Teva Pharmaceuticals faces a $27.6 million settlement to resolve False Claims Act allegations accusing the company of paying kickbacks to a physician to prescribe the company’s anti-psychotic drug.
8. Pharmaceutical companies are scaling back payments to healthcare professionals who promote their drugs.
More Articles on Supply Chain:
FDA Clears Intuitive Surgical’s Latest da Vinci Robot Upgrade
Steris to Acquire Integrated Medical Systems for $165M
6 Alternatives to Ease the Nitroglycerin Shortage
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
